FDA provides GDUFA guidance; Lilly bets big on continuous processing; Edible tags noted for fighting counterfeits;

> The FDA has revised draft guidance on the Generic Drug User Fee Amendments of 2012 (GDUFA). Document (PDF)

> Eli Lilly ($LLY) by next year expects to be using four different continuous processing platforms for production of many of its new products. Story

> The University of Iowa Pharmaceuticals (UIP) has been approved to handle the commercial manufacturing of Valchor (mechlorethamine) gel for Ceptaris Therapeutics. Release

> Taiwan's ScinoPharm say its Tainan, Taiwan, plant has been approved to manufacture the API for Supernus Pharmaceuticals' Trokendi XR, a once-daily extended release formulation of topiramate for the treatment of epilepsy. Release

> The FDA has approved Sanofi's ($SNY) manufacturing site in Compiegne, France, to manufacture Duexis, a combo of ibuprofen and famotidine tablet from Horizon Pharma ($HZNP). Release

> Unilife says it has a new contract for Sanofi to buy a minimum of 150 million of its Unifill Finesse prefilled syringes for use with Lovenox and Clexane. Report

And Finally... TruTag Technologies, a Honolulu-based company, has been named a 2014 Technology Pioneer by the World Economic Forum for its edible tags for use in fighting drug and food counterfeiting. Release